Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04739267 · ClinicalTrials.gov registry record

Acute Coronary Syndrome CardioFlux TM Study (ACCMED)

A clinical trial, sponsored by Genetesis.

Completed
Registry status
390
Enrollment target

NCT04739267 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 390 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04739267 has completed, sponsored by Genetesis.

COMPLETED
Registry status
390 participants
Enrollment target

Study Summary

Approximately 16.5 million people suffer from coronary artery disease (CAD) and about 10 million present each year to emergency departments with symptoms like chest pain and shortness of breath, commonly suggestive of acute coronary syndrome (ACS). To clinically assess ACS risk in these patients, there are typically 2-6 hours of emergency room evaluation, followed by 6-42 hours of an observation period prior to discharge. The clinical pathway includes: 1) 1-3 ECG's; 2) serial troponins (1 and 3 hours vs 1 and 6 hours); and 3) other pertinent diagnostic information, including but not limited to echocardiography, stress testing and/or CT Angiography. Patients who are evaluated, have presented with a low risk for ACS, and maintain negative diagnostic results can potentially be discharged within 6 hours. However, 20%-40% of patients who fall into indeterminate diagnostic categories will require longer observation periods or admission of 12-48 hours which result in the use of expensive imaging and provocative testing, such as stress testing. The purpose of ACCMED is to measure the efficacy of Magnetocardiography (MCG) as a diagnostic tool to rule-in/rule-out myocardial ischemia in patients with suspicion of an acute coronary syndrome who have a HEART Score \> 2 and to allow safe and timely disposition of the patient to an appropriate level of care.

Interventions

  • DEVICE CardioFlux

Trial Details

FieldValue
Enrollment Target 390 participants
Start Date 2021-01-27
Est. Completion 2023-03-03

Sponsor

Genetesis

9 total trials

What the Registry Record Tells You About NCT04739267

The ClinicalTrials.gov registry entry for NCT04739267 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetesis, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which CardioFlux is the first listed.

NCT04739267 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04739267 about?

NCT04739267 is a clinical study titled "Acute Coronary Syndrome CardioFlux TM Study (ACCMED)". Approximately 16.5 million people suffer from coronary artery disease (CAD) and about 10 million present each year to emergency departments with symptoms like chest pain and shortness of breath, commonly suggestive of acute coronary syndrome (ACS). To clinically assess ACS risk in these patients, th...

What is the current status of trial NCT04739267?

This trial is currently completed. The enrollment target is 390 participants. The study started on 2021-01-27. Estimated completion is 2023-03-03.

What interventions are being tested in trial NCT04739267?

The interventions under investigation include: CardioFlux (DEVICE).

Who is sponsoring clinical trial NCT04739267?

This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.